AstraZeneca follows Merck with Phase 3 win in bladder cancer

AstraZeneca has announced positive results from a Phase 3 trial for its bladder cancer treatment, combining its drug Imfinzi with Pfizer and Astellas’ Padcev. This combination demonstrated a higher survival rate for patients compared to the standard treatment. The company plans to seek regulatory approval for this new therapy.